Assessment of Stability of Behavioral and Neural Measures of Attention Networks Across Multiple Sessions

February 21, 2020 updated by: University of Florida
The purpose of this research study is to learn more about the stability over multiple recording sessions of brainwave activity during a computerized task that measures different types of attention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Attention is the backbone of cognitive systems and is requisite for other cognitive processes vital to everyday functioning, such as memory, problem solving, language skills, and the cognitive control of behavior. Impairments in attention can result from a variety of factors, such as brain injury, and neurodegenerative and neurodevelopmental disorders, as well as various psychopathologies. A prominent multi-component model of visuospatial attention developed by Posner and colleagues conceptualizes visuospatial attention as an "organ system" comprised of three independent, yet interactive networks which include: 1) Alerting, the generation and maintenance of a vigilant state that facilitates the processing of an upcoming stimulus, 2) Orienting, the disengagement, shifting, and reallocation of attention to a spatial location, and 3) Executive control, the resolution of conflict among competing mutually-exclusive responses that enables selective focus. To aid in understanding of attention, the Attention Network Test (ANT) was developed as a brief computerized measure of the efficiency of each of these networks and has been extensively used in a variety of healthy and clinical populations. Several studies have examined differences in ERPs during the ANT in healthy aging and clinical populations such as ADHD, schizophrenia, and traumatic brain injury (TBI) but have not conducted repeated sessions of the task to evaluate changes over time. While the ANT has been shown to be robustly sensitive to a range of cognitive and/or neuropsychological disorders, the reliability of the ANT across multiple sessions, particularly in terms of neural activity measures, has not been previously examined. An important focus of the proposed research regards the stability of neural measures reflecting activity of each of three different attention networks. One method for examining neural activity involves time locked electroencephalographic (EEG) recordings of brain activity or scalp-recorded brain event-related potentials (ERPs). ERPs can provide insights into the neural correlates of cognitive processes elicited by an experimental task as well as the neural time course. Particularly relevant to this study, the visual N1, a negative-going ERP deflection occurring ~150-200 milliseconds (ms) post-stimulus. N1 amplitude is considered to index attentional allocation. Additionally, a later-occurring positive-going deflection occurring ~300-ms post-stimulus, P3, reflects processes associated with stimulus evaluation and categorization. Previous research in our lab has shown that N1 and P3 are differentially sensitive to attention network functioning probed using the ANT in neurologically-healthy controls and are sensitive to attentional impairment in TBI survivors. Thus, the study team will focus on the stability of N1 and P3 waveforms across the 4 sessions. Previous studies have examined reliability and stability of behavioral measures of the ANT by evaluating the reliability of reaction time (RT) and error rates over multiple sessions. Ishigami reported good temporal stability of network scores across 10 sessions, although some practice effects were seen in orienting and executive-control attention networks. Importantly, no prior work has examined the temporal stability of ERPs with repeated ANT performance, which is among the primary aims of the proposed research. Finally, in an exploratory manner, the investigators will extend findings from one of our earlier studies demonstrating altitudinal attentional biases for upper vertical space in healthy participants and the absence of such biases in TBI survivors. Specifically, the investigators will examine which of three attentional networks are sensitive to such biases in healthy controls and determine the ERP signatures of these biases.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
16

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Florida
      • Gainesville, Florida, United States, 32611
        • College of Public Health and Health Professions, University of Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Healthy Controls

Description

Inclusion Criteria:

  • right-hand dominant
  • Native English speakers
  • with normal or corrected-to-normal vision

Exclusion Criteria:

  • Not right-hand dominant
  • Does not speak english as a native language
  • No history of neurological disorder such as stroke, epilepsy or chronic seizure disorder, traumatic brain injury or concussion, psychiatric disorder such as schizophrenia, bipolar disorder, major depression or anxiety disorder, any psychiatric inpatient hospitalization for any of these disorders, or previously diagnosed learning disability
  • Currently taking any prescribed medications for anxiety, depression, or seizures
  • Alcohol use more than 3 days a week

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Controls
Participants will include 15 healthy men and women aged 18-40 years, right-hand dominant, Native English speakers, with normal or corrected-to-normal vision.
Behavioral: Attention Network Task
The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
Other Names:
  • Electroencephalography

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in the temporal stability of behavioral measures of three attention networks: change in reaction time across four sessions
Time Frame: Week 1; Week 2; Week 3; Week 4
The Attention Network Task (ANT) combines a covert cuing paradigm with a classic flanker task to behaviorally probe independent but interactive components of attention. These distinct components of attention are: alerting, orienting, and executive control. These facets of attention will be assessed at 4 time points scheduled 1 week apart as follows: ANT Alerting Reaction Time score, ANT Orienting Reaction Time score and ANT Executive-control Reaction Time score. The lower the score the faster the reaction time.
Week 1; Week 2; Week 3; Week 4
Change in the temporal stability of neural measures of three attention networks using scalp-recorded electroencephalography (EEG)
Time Frame: Week 1; Week 2; Week 3; Week 4
Scalp-recorded brain event related potentials (ERP) will be acquired from 64 EEG sensors while participants perform the ANT reflecting alerting, orienting, and executive control components of attention. These facets of attention will be assessed at 4 time points scheduled 1 week apart. ANT alerting will be interrogated by examining the amplitude of the P300 component of the ERP in microvolts, as will orienting and executive-control.
Week 1; Week 2; Week 3; Week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Florida

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: William Perlstein, PhD, University of Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 31, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 8, 2019

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 8, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 19, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 25, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 26, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 24, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 21, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IRB201600188
  • 0217BBRC-02 (Other Grant/Funding Number: *NF/SGVHS Malcom Randall VA Medical Cent)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Network Task

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings